Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

Rhea-AI Summary

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, purchased 7,000 common shares at $0.69 each. With this transaction, Cerrone's overall interest in Tiziana remains significant at 37.70%. Tiziana focuses on innovative drug delivery technologies for immunotherapies, including its lead candidates: intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor. These candidates are showing favorable safety profiles and responses in clinical studies.

Positive

• Panetta Partners Limited purchased 7,000 shares at $0.69, showing confidence in the company.
• Cerrone maintains a substantial interest of 37.70%, indicating commitment to shareholders.
• Lead candidate foralumab, a fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have favorable clinical responses.

Negative

• None.

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 7,000 common shares at $0.69 per share.

Mr Cerrone's interests remain at 37.70%.

About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further inquiries:

Tiziana Life Sciences Ltd Hana Malik, Business Development, and Investor Relations Manager   +44 (0) 207 495 2379 email: info@tizianalifesciences.com
Investors: Irina Koffler LifeSci Advisors, LLC 646.970.4681 ikoffler@lifesciadvisors.com

FAQ

What recent stock purchase was made by Tiziana Life Sciences' Executive Chairman?

Gabriele Cerrone's associated entity, Panetta Partners Limited, purchased 7,000 common shares at $0.69 each.

What percentage of Tiziana does Gabriele Cerrone own after the recent share purchase?

Gabriele Cerrone's ownership interest in Tiziana remains at 37.70%.

What are the lead candidates in Tiziana Life Sciences' pipeline?

Tiziana's lead candidates include intranasal foralumab and milciclib.

What is the primary focus of Tiziana Life Sciences?

Tiziana focuses on developing innovative immunotherapies using novel routes of drug delivery.

What is the significance of foralumab in Tiziana's development?

Foralumab is the only fully human anti-CD3 monoclonal antibody, showing favorable safety and clinical response.